New Delhi: Accenture’s Life Sciences Technology Vision 2022 report explores the technology trends that will transform how biopharmaceutical and medical technology companies solve manufacturing and device problems, improve equity in clinical trial participation and build more resilient supply chains to provide patients and healthcare professionals with more personalised experiences.
According to the report, life sciences leaders, which includes 91 per cent of medical technology executives and 85 per cent biopharma executives, expect the metaverse to have a positive impact on their organisations and nearly half of the biopharma executives surveyed believe the metaverse will have a breakthrough or transformational impact on their organisations.
Sameer Amte, lead for life sciences at Accenture in India, said “Driving the next wave of digital transformation, the metaverse can help companies provide more personalised experiences for both patients and healthcare professionals across the value chain such as sales, manufacturing, supply chain, training among others. For future growth and competitiveness, life sciences companies in India need to act now and build their capabilities for a new digital future enabled by the metaverse.”
To help life sciences companies design, execute and accelerate their metaverse journeys, Accenture recently launched the Accenture Metaverse Continuum business group, which combines metaverse-skilled professionals and market-leading capabilities in customer experience, digital commerce, extended reality, blockchain, digital twins, artificial intelligence, and computer vision.
In the report, four technology trends that underpin the metaverse continuum are explored:
1. WebMe illustrates how the internet is being reimagined with the metaverse as a platform for digital experiences that provide boundless places where people can meet and interact, and Web3 is reinventing how data can be owned by individuals and moved with the person and not the platform.
2. The Programmable World tracks how technology is being threaded through our physical environments in three layers: connected, experiential, and material. Nearly nine-in-10 of the MedTech and biopharma executives surveyed believe that programming the physical environment will emerge as a competitive differentiation in their industry. Augmented reality, 5G, ambient computing, 3D printing, and smart materials are converging in sophisticated ways, turning the physical world into an environment that is as smart, customisable, and as programmable as the digital one.
3. The Unreal explores the ‘unreal’ qualities that are becoming fundamental to artificial intelligence (AI), and even data, making the synthetic seem authentic. Synthetic data can represent patient datasets for use in research, training, or other applications. This realistic (yet unreal) data can be shared, maintaining the same statistical properties while protecting confidentiality and privacy. More than nine-tenths of biopharma (92 per cent) and MedTech (91 per cent) executives report that their organisation is dependent on AI technologies to function effectively.
4. Computing the Impossible is the emergence of a new class of machines — quantum computing — stretching the boundaries of what computers can do.. Nearly all the surveyed biopharma (94 per cent) and MedTech (96 per cent) executives agree that their organisation is pivoting in response to the unprecedented computational power that is becoming available.